Issued 2026-08-13 at $117.60 · now $116.02 (2026-08-13, −1.3% since)
Based on its own history, a month from the 2026-08-13 close, RYTM has typically landed between $93.94 and $165.41 — a range of −20.1% to +40.7% from the issuance price $117.60.
- Actual close
- Typical path (median)
- Middle 50% of outcomes
- 90% range
2,204 overlapping 1 month windows · 2017-10-05 – 2026-07-15 · basis climatology · forecast (batch). Probability up 53.8% (90% CI 51.6–56.0%, ≈1,400 obs).
The cone is anchored at the 2026-08-13 issuance close ($117.60) — the price the forecast resolves against on 2026-09-11, not the latest close. The drawn path shape is illustrative (bands widen with √t); every labeled number is real — the anchor, the scored batch p90/IQR endpoints, and the typical move.
Where RYTM has typically landed a month from the 2026-08-13 close of $117.6 — the range is history, not a prediction.
- now $116.02 (-1.3%)
- typicalThe typical outcome — half of similar past periods did better and half did worse (not an average, so a few wild periods don't skew it). $119.11 (+1.3%)
- middle 50%The central range of outcomes — half of similar past periods landed inside it, a quarter finished above, a quarter below. $105.89–$132.34
- 90% rangeA nine-in-ten range — in about nine of every ten similar past periods the outcome stayed within these bounds. $93.94–$165.41
| Start | Return | Max drop | Max rise |
|---|---|---|---|
| 3 worst | |||
| 2022-04-13 | −65.2% | −65.2% | +0.0% |
| 2022-04-14 | −63.6% | −63.6% | +0.0% |
| 2022-04-08 | −62.5% | −62.5% | +1.3% |
| 3 best | |||
| 2022-07-11 | +382.9% | +0.0% | +382.9% |
| 2022-07-08 | +332.1% | −4.1% | +332.1% |
| 2022-07-07 | +325.2% | −1.5% | +325.2% |
2,204 overlapping windows · 2017-10-05 – 2026-08-13 · not cherry-picked
Pending catalysts
- 2026-10-31 — Trial primary completion: Phase 2 primary completion: A Study of Setmelanotide in Patients With Prader-Willi Syndrome (source, as of 2026-08-14)
- 2027-03-13 — Trial primary completion: Phase 3 primary completion: A Trial of Setmelanotide in Patients With Congenital Hypothalamic Obesity (Sub-study of NCT05774756) (source, as of 2026-08-14)
- 2027-11-01 — Trial primary completion: Phase 1/Phase PHASE2 primary completion: A Study of RM-718 in Healthy Subjects and Patients With MC4R Pathway Impairment (source, as of 2026-08-14)
- 2028-04-15 — Trial primary completion: Phase 2 primary completion: A Long-Term Study of Bivamelagon in Participants With Hypothalamic Obesity (HO) (source, as of 2026-08-14)
Public, scheduled events — dated attention, not a prediction of the outcome. See the FDA catalysts page for the historical base rate.
Seasonality · by month iHow this security has tended to do in each calendar month historically — a frequency, never a prediction.
iFor each calendar month, the share of years this security closed higher than the month before, and the average month-over-month return, over ~9 years of its own price history. Cells are shaded by average return. This is historical frequency, not a prediction — no month is a signal.Up-frequency and average month-over-month return · historical frequency, not a prediction
Company insiders iOpen-market share purchases and sales by the company's own officers and directors, by filing date.
Last 90 days · as of 2026-08-13 · point-in-time by filing date
No insider transactions on record in the last 90 days.
Congressional disclosures
No congressional trades disclosed for this company.
Research tool, not investment advice — historical frequencies, not recommendations. Full terms.